Epidemiology of CF: How registries can be used to advance our understanding of the CF population

National Institute of Health - National Cancer Institute 2002 European Commission Health & Consumer Protection Directorate General Smyth, 2014, European cystic fibrosis society standards of care: best practice guidelines, J Cyst Fibros, 13, S23, 10.1016/j.jcf.2014.03.010 Knapp, 2016, The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry, Ann Am Thorac Soc, 13, 1173, 10.1513/AnnalsATS.201511-781OC MacKenzie, 2014, Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry, Ann Intern Med, 161, 233, 10.7326/M13-0636 Mayer-Hamblett, 2002, Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality, Am J Respir Crit Care Med, 166, 1550, 10.1164/rccm.200202-087OC Burgel, 2015, Future trends in cystic fibrosis demography in 34 European countries, Eur Respir J, 46, 133, 10.1183/09031936.00196314 De Boeck, 2017, Year to year change in FEV1 in patients with cystic fibrosis and different mutation classes, J Cyst Fibros, 16, 239, 10.1016/j.jcf.2016.09.009 Cystic Fibrosis Australia Cystic Fibrosis Canada Cystic Fibrosis Foundation Patient Registry Cystic Fibrosis New Zealand Cystic Fibrosis Registry of Ireland Cystic Fibrosis Trust Nahrlich Nederlanse Cystic Fibrosis Stichting The Brazilian Cystic Fibrosis Registry Vaincre la Mucoviscidose and Institut National d'Études Démographiques (Ined) Wanyama Zolin Viviani Conway, 2014, European cystic fibrosis society standards of care: framework for the cystic fibrosis Centre, J Cyst Fibros, 13, S3, 10.1016/j.jcf.2014.03.009 Mehta, 2010, Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries, J Cyst Fibros, 9, S5, 10.1016/j.jcf.2010.08.002 Viviani, 2014, The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry, Orphanet J Rare Dis, 9, 81, 10.1186/1750-1172-9-81 NHS England Specialised Services Personal Health Budgets: NHS Schechter, 2014, The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement, BMJ Qual Saf, 23, i9, 10.1136/bmjqs-2013-002378 Healthcare Cost and Utilisation Project Morgan, 1999, Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada, Pediatr Pulmonol, 28, 231, 10.1002/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2 Taylor-Robinson, 2013, The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study, Lancet Respir Med, 1, 121, 10.1016/S2213-2600(13)70002-X Jackson, 2011, Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis, Thorax, 66, 674, 10.1136/thoraxjnl-2011-200038 2017 Kulich, 2003, Improved survival among young patients with cystic fibrosis, J Pediatr, 142, 631, 10.1067/mpd.2003.197 Dasenbrook, 2010, Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis, JAMA, 303, 2386, 10.1001/jama.2010.791 Liou, 2001, Predictive 5-year survivorship model of cystic fibrosis, Am J Epidemiol, 153, 345, 10.1093/aje/153.4.345 Kerem, 1992, Prediction of mortality in patients with cystic fibrosis, N Engl J Med, 326, 1187, 10.1056/NEJM199204303261804 Sanders, 2010, Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation, Am J Respir Crit Care Med, 182, 627, 10.1164/rccm.200909-1421OC Sanders, 2010, Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis, Pediatr Pulmonol, 45, 127, 10.1002/ppul.21117 Rothman, 2003, Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation, Epidemiology, 14, 55, 10.1097/00001648-200301000-00014 Sawicki, 2012, Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution, Pediatr Pulmonol, 47, 44, 10.1002/ppul.21521 Ren, 2008, Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis, J Pediatr, 153, 746, 10.1016/j.jpeds.2008.07.010 Konstan, 2017, Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study, Lancet Respir Med, 5, 107, 10.1016/S2213-2600(16)30427-1 VanDyke, 2013, Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis, Ann Am Thorac Soc, 10, 205, 10.1513/AnnalsATS.201209-082OC Stephenson, 2017, Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study, Ann Intern Med, 166, 537, 10.7326/M16-0858 FitzSimmons, 1993, The changing epidemiology of cystic fibrosis, J Pediatr, 122, 1, 10.1016/S0022-3476(05)83478-X Nick, 2010, Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis, Am J Respir Crit Care Med, 182, 614, 10.1164/rccm.201001-0092OC Stephenson, 2015, Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis, J Heart Lung Transplant, 34, 1139, 10.1016/j.healun.2015.05.003 Salsgiver, 2016, Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis, Chest, 149, 390, 10.1378/chest.15-0676 Marshall, 2005, Epidemiology of cystic fibrosis-related diabetes, J Pediatr, 146, 681, 10.1016/j.jpeds.2004.12.039 Smyth, 2008, Case-control study of acute renal failure in patients with cystic fibrosis in the UK, Thorax, 63, 532, 10.1136/thx.2007.088757 Bosch, 2017, Ethnicity impacts the cystic fibrosis diagnosis: a note of caution, J Cyst Fibros, 16, 488, 10.1016/j.jcf.2017.01.016 Kerem Corey, 1988, A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto, J Clin Epidemiol, 41, 583, 10.1016/0895-4356(88)90063-7 Sosnay, 2013, Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene, Nat Genet, 45, 1160, 10.1038/ng.2745 Sims, 2009, International benchmarking for cystic fibrosis patient outcomes using registry data, J Cyst Fibros, 8, S103, 10.1016/S1569-1993(09)60399-4 Sims Sykes, 2016, A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts, J Clin Epidemiol, 70, 206, 10.1016/j.jclinepi.2015.08.026 O'Donnell O'Donnell Sabadosa, 2014, The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the coproduction of healthcare and its improvement, BMJ Qual Saf, 23, i90, 10.1136/bmjqs-2013-002782 Godfrey, 2014, Accelerating the rate of improvement in cystic fibrosis care: contributions and insights of the learning and leadership collaborative, BMJ Qual Saf, 23, i23, 10.1136/bmjqs-2014-002804 Marshall, 2014, Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative, BMJ Qual Saf, 23, i95, 10.1136/bmjqs-2013-002790 Panagioti, 2014, Self-management support interventions to reduce health care utilisation without compromising outcomes: a systematic review and meta-analysis, BMC Health Serv Res, 14, 356, 10.1186/1472-6963-14-356 Lorig, 2001, Effect of a self-management program on patients with chronic disease, Eff Clin Pract, 4, 256 Cystic Fibrosis Foundation